Newsroom | 69164 results
Sorted by: Latest
-
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending December 31 of each year. There was an eight-month transition period from May 1, 2025 to December 31, 2025 and these results are presented within the condensed consolidated finan...
-
Riassunto: Prodalim rafforza la sua piattaforma funzionale per entrare nel mercato in rapida crescita dei prodotti nutraceutici con l'acquisizione di Sylvestre, un leader del mercato degli estratti botanici con sede in Brasile
Winter Garden, Florida--(BUSINESS WIRE)--Prodalim, leader globale nelle soluzioni per beverages and food industry, ha annunciato oggi l'acquisizione di Sylvestre, produttore brasiliano leader nel settore degli estratti botanici e funzionali rivolto al mercato dei prodotti nutraceutici. Gli attuali titolari e l'amministrazione di Sylvestre rimarranno nella società e ne supporteranno l'integrazione nella piattaforma di Prodalim. Fondata in Brasile nel 1992, Sylvestre è un'azienda produttrice e fo...
-
Space Quarters Successfully Demonstrates Space Welding Technology for Metals and Regolith-based Construction Materials Under Ultra-high Vacuum, Microgravity, and Lunar Gravity Conditions Toward Realizing Space Architecture
TOKYO--(BUSINESS WIRE)--Space Quarters Inc. has successfully conducted aircraft-based demonstration tests of space welding for metals and lunar regolith-based construction materials under space-equivalent ultra-high vacuum and simulated microgravity and lunar gravity. Under conditions comparable to construction in space, the company confirmed sound joints and sufficient bonding strength. Space Welding Demonstration through Aircraft-Based Testing A high-vacuum chamber was mounted on an aircraft...
-
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you jo...
-
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under th...
-
X-lumin Achieves Roundtrip Optical Transmission to LEO Satellite Using 15cm Portable Terminal
MERRITT ISLAND, Fla.--(BUSINESS WIRE)--X-lumin has successfully demonstrated a roundtrip optical transmission from its 15cm Optical Ground Terminal (OGT) to a retroreflector-equipped LEO satellite, and back, with the ability to track downlink signals that are 106 times dimmer than the current standard of 25µW/m2. The demonstration was repeated over multiple passes during recent testing, marking the first time a portable, low SWaP (Size, Weight, Power) terminal has closed a roundtrip optical lin...
-
Riassunto: Biocytogen annuncia una collaborazione strategica con Moonlight Bio per promuovere le terapie cellulari utilizzando una libreria di anticorpi leganti
PECHINO--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), un’azienda biotecnologica globale che dà impulso alla ricerca e sviluppo di farmaci innovativi basati su anticorpi impiegando tecnologie all’avanguardia, oggi ha annunciato una collaborazione strategica con Moonlight Bio, Inc., società biotecnologica con sede a Seattle, pioniera nelle terapie cellulari all’avanguardia. Questa collaborazione mira a sviluppare terapie cellulari all’ava...
-
Roseman University Launches Roseman Bioventures, a 120,000-square-foot Life Science Incubator in Las Vegas
LAS VEGAS--(BUSINESS WIRE)--Roseman Bioventures aims to accelerate the commercialization of life science innovations and expand the Nevada biotech ecosystem....
-
HJS FoundationがJEPプロトコルとHJSフレームワークを公開:AIの「ブラックボックス」として検証可能な人間の監視を実現
シンガポール--(BUSINESS WIRE)--(ビジネスワイヤ) -- HJS Foundation(Human Judgment Systems Foundation)は、2つの補完的なソリューション「Judgment Event Protocol(JEP)」と「Human Judgment Structure(HJS)」フレームワークを公開しました。ミニマリストなオープン・スタンダードであるJEPは、航空機のブラックボックスと同様に、改ざんできないAIの意思決定における説明責任の記録を生成します。そして、HJSは人間の判断ロジックをAIの運用プロセスに組み込みます。両者を組み合わせることで、「人間による監視」を規制上の要件から検証可能な技術的事実へと転換し、AIの説明責任に対するオプションの技術的ソリューションを提供します。 これで、融資審査、医療診断、入国審査などのAIによる意思決定が人間にレビューされていることを証明できるようになりました。JEPは、Judge、Verify、Delegate、Terminateという4つの暗号プリミティブを通じて、人間の介入に関する不変の...
-
HJS Foundation发布JEP协议与HJS框架:AI的“黑匣子”,实现可验证的人类监督
新加坡--(BUSINESS WIRE)--(美国商业资讯)-- 人类判断系统基金会(HJS Foundation)今日发布两项互补解决方案:判断事件协议(JEP)和人类判断架构(HJS)框架。作为极简开放标准,JEP能生成防篡改的AI决策问责记录,如同飞机黑匣子一般;HJS则将人类判断逻辑嵌入AI运行流程——二者协同作用,将“人类监督”从监管要求转化为可验证的技术事实,为AI问责提供了可选技术方案。 如何证明AI决策(如贷款审批、医疗诊断、边境检查等)经过了人类审核? JEP通过判断(Judge)、验证(Verify)、委托(Delegate)、终止(Terminate)四大加密原语,生成不可篡改的人类干预审计轨迹;HJS则构建可控、可问责的系统,防范AI漂移等风险,确保人类判断能指导AI运行。 当前系统依赖可修改的事后文档记录,而JEP和HJS则协同工作:JEP如同飞机黑匣子,不评判表现如何,只确保可追溯性;HJS则将人类监督嵌入AI工作流程——二者共同为监管机构、开发者和用户提供无可辩驳的事实依据。 JEP协议与HJS框架搭配使用,为可信AI提供了合规技术选项。它们共同实现了跨平...